Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC48-ADC + Pyrotinib in HER2-mutated NSCLC
NCT05745740Phase 2Not yet recruiting
- Sponsor
- RemeGen
- Start
- Dec 2027
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of disitamab vedotin in non-small cell lung cancer (NSCLC), sponsored by RemeGen. Planned start Dec 2027; status: not yet recruiting.
02
Drugs
disitamab vedotin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05745740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05745740.